The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.
暂无分享,去创建一个
[1] Ulrich Siebenlist,et al. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.
[2] I. Sanz,et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. , 2004, Arthritis and rheumatism.
[3] S. Shinton,et al. Resolution of Three Nonproliferative Immature Splenic B Cell Subsets Reveals Multiple Selection Points During Peripheral B Cell Maturation1 , 2001, The Journal of Immunology.
[4] T. Habermann,et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. , 2004, Blood.
[5] A. Basten,et al. Reduced life span of anergic self-reactive B cells in a double- transgenic model , 1994, The Journal of experimental medicine.
[6] C. Ni,et al. Key Molecular Contacts Promote Recognition of the BAFF Receptor by TNF Receptor-Associated Factor 3: Implications for Intracellular Signaling Regulation1 , 2004, The Journal of Immunology.
[7] J. V. van Deursen,et al. Regulation of the T-independent humoral response by TACI. , 2001, Immunity.
[8] T. Phan,et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. , 2004, Immunity.
[9] S. Nish,et al. The regulation and activation potential of autoreactive B cells , 2003, Immunologic research.
[10] J. Tschopp,et al. Baff Binds to the Tumor Necrosis Factor Receptor–Like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population , 2000, The Journal of experimental medicine.
[11] M. Nussenzweig,et al. Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.
[12] P. Schneider,et al. BAFF, APRIL and their receptors: structure, function and signaling. , 2006, Seminars in immunology.
[13] B. Diamond,et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. , 2006, The Journal of clinical investigation.
[14] M. Petri. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort , 2000, Lupus.
[15] M. Scott,et al. An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway , 2001, Science.
[16] T. McGaha,et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. , 2008, Blood.
[17] P. Moore,et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. , 2001, Blood.
[18] T. Cachero,et al. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. , 2002, Journal of molecular biology.
[19] M. Dalakas,et al. B cells as therapeutic targets in autoimmune neurological disorders , 2008, Nature Clinical Practice Neurology.
[20] G. Burmester,et al. New approaches of B-cell-directed therapy: beyond rituximab , 2008, Current opinion in rheumatology.
[21] N. Kamatani,et al. Excessive Production of IFN-γ in Patients with Systemic Lupus Erythematosus and Its Contribution to Induction of B Lymphocyte Stimulator/B Cell-Activating Factor/TNF Ligand Superfamily-13B1 , 2008, The Journal of Immunology.
[22] G. Bishop,et al. Mechanisms of TNF receptor‐associated factor (TRAF) regulation in B lymphocytes , 2002, Journal of leukocyte biology.
[23] C. Grimaldi,et al. Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus1 , 2004, The Journal of Immunology.
[24] K. Costenbader,et al. What can epidemiology tell us about systemic lupus erythematosus? , 2007, International journal of clinical practice.
[25] C. Mok. Therapeutic options for resistant lupus nephritis. , 2006, Seminars in arthritis and rheumatism.
[26] V. Pascual,et al. Dendritic cells control B cell growth and differentiation. , 2005, Current directions in autoimmunity.
[27] X. Mariette,et al. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome , 2004, The Journal of pathology.
[28] M. Nussenzweig,et al. A checkpoint for autoreactivity in human IgM+ memory B cell development , 2006, The Journal of experimental medicine.
[29] J. Sibilia. Novel concepts and treatments for autoimmune disease: ten focal points. , 2004, Joint, bone, spine : revue du rhumatisme.
[30] M. Cancro,et al. Space, Selection, and Surveillance: Setting Boundaries with BLyS1 , 2006, The Journal of Immunology.
[31] C. Gordon,et al. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. , 2005, Best practice & research. Clinical rheumatology.
[32] G. Hughes,et al. Systemic lupus erythematosus , 2001, The Lancet.
[33] N. Rose. Autoimmune diseases. , 1981, Scientific American.
[34] D. Landau,et al. The B lymphocyte stimulator receptor–ligand system in hepatitis C virus-induced B cell clonal disorders , 2008, Annals of the rheumatic diseases.
[35] Meit A. Bjorndahl,et al. Articles on similar topics can be found in the following Blood collections , 2006 .
[36] M. Peterson,et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. , 2005, Arthritis and rheumatism.
[37] C. Gregory,et al. Enhanced Apoptotic Cell Clearance Capacity and B Cell Survival Factor Production by IL-10-Activated Macrophages: Implications for Burkitt’s Lymphoma1 , 2005, The Journal of Immunology.
[38] D. Gladman,et al. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus , 2007, Annals of the rheumatic diseases.
[39] J. Tschopp,et al. BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF , 2001, Science.
[40] J. Monroe,et al. Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling , 2008, Nature Immunology.
[41] B. Nardelli,et al. G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS , 2003, The Journal of experimental medicine.
[42] F. Mackay,et al. B cells flying solo , 2008, Immunology and cell biology.
[43] M. Petri. Monitoring systemic lupus erythematosus in standard clinical care. , 2007, Best practice & research. Clinical rheumatology.
[44] M. Cancro,et al. Bcmd decreases the life span of B-2 but not B-1 cells in A/WySnJ mice. , 1998, Journal of immunology.
[45] W. Anderson,et al. Residues that mediate DNA binding of autoimmune antibodies. , 1993, Journal of immunology.
[46] J. Tschopp,et al. Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations , 1999, The Journal of experimental medicine.
[47] J. Cyster,et al. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire , 1994, Nature.
[48] V. Dixit,et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency , 2001, Current Biology.
[49] J. Green,et al. The association of HLA‐linked genes with systemic lupus erythematosus , 1986, Annals of human genetics.
[50] M. Hochberg,et al. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.
[51] R. Voll,et al. SLE--a disease of clearance deficiency? , 2005, Rheumatology.
[52] D. Lawrence,et al. APRIL-Deficient Mice Have Normal Immune System Development , 2004, Molecular and Cellular Biology.
[53] J. Satia,et al. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden , 2006, Lupus.
[54] C. Janeway,et al. A B-cell receptor-specific selection step governs immature to mature B cell differentiation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[55] H. Shu,et al. B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[56] R. Geha,et al. TACI is mutant in common variable immunodeficiency and IgA deficiency , 2005, Nature Genetics.
[57] M. Liang,et al. The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the "prevalence gradient hypothesis". , 1998, Arthritis and rheumatism.
[58] B. Seed,et al. B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells1 , 2005, The Journal of Immunology.
[59] M. Crow,et al. Interferon-α in systemic lupus erythematosus , 2004 .
[60] Amy S Orr,et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. , 1999, Science.
[61] M. Pelletier,et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.
[62] Yun Hee Cho,et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact , 2008, Proceedings of the National Academy of Sciences.
[63] H. Shu,et al. Crystal Structure of sTALL-1 Reveals a Virus-like Assembly of TNF Family Ligands , 2002, Cell.
[64] A. Basten,et al. Whither the anergic B-cell? , 1994, Autoimmunity.
[65] V. Roschke,et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. , 2003, Arthritis and rheumatism.
[66] D. Lacey,et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[67] R. Siegel,et al. Cardiovascular manifestations of systemic lupus erythematosus. , 1985, American heart journal.
[68] M. Cancro,et al. The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. , 2007, International immunology.
[69] C. Ware,et al. ΔBAFF, an Alternate Splice Isoform That Regulates Receptor Binding and Biopresentation of the B Cell Survival Cytokine, BAFF* , 2003, Journal of Biological Chemistry.
[70] R. Geha,et al. Impaired IgA class switching in APRIL-deficient mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[71] V. Roschke,et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. , 2003, Arthritis and rheumatism.
[72] B. Nardelli,et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL , 2002, Nature Immunology.
[73] K. Rajewsky,et al. Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. , 2006, Immunity.
[74] D. Hilbert,et al. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers , 2001, Current Biology.
[75] D. Danilenko,et al. Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. , 2007, Blood.
[76] R. Geha,et al. Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL1 , 2008, The Journal of Immunology.
[77] M. Cancro,et al. Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. , 1993, Journal of immunology.
[78] D. Isenberg,et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.
[79] D. Nemazee,et al. Clonal deletion of autoreactive B lymphocytes in bone marrow chimeras. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[80] B. Aggarwal,et al. Identification and Characterization of a Novel Cytokine, THANK, aTNF Homologue That ActivatesApoptosis, Nuclear Factor-κB, and c-Jun NH2-Terminal Kinase* , 1999, The Journal of Biological Chemistry.
[81] C. Hayes,et al. Enforced bcl-xL Gene Expression Restored Splenic B Lymphocyte Development in BAFF-R Mutant Mice1 , 2003, The Journal of Immunology.
[82] J. Tschopp,et al. BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth , 1999, The Journal of experimental medicine.
[83] R. Brink,et al. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. , 2004, Immunity.
[84] E. Clark,et al. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway , 2005, The Journal of experimental medicine.
[85] R Hal Scofield,et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.
[86] Don Foster,et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease , 2000, Nature.
[87] P. Sideras,et al. B Cell Development in the Spleen Takes Place in Discrete Steps and Is Determined by the Quality of B Cell Receptor–Derived Signals , 1999, The Journal of experimental medicine.
[88] G. Burmester,et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus , 2006, Arthritis research & therapy.
[89] R. Hardy,et al. B cell development pathways. , 2001, Annual review of immunology.
[90] J. Merrill,et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus , 2008, Arthritis research & therapy.
[91] M. Scott,et al. Cutting Edge: BAFF Regulates CD21/35 and CD23 Expression Independent of Its B Cell Survival Function , 2004, The Journal of Immunology.
[92] S. Camper,et al. Receptor editing: an approach by autoreactive B cells to escape tolerance , 1993, The Journal of experimental medicine.
[93] G. Bishop. The multifaceted roles of TRAFs in the regulation of B-cell function , 2004, Nature Reviews Immunology.
[94] G. Nossal,et al. Evidence for the clonal abortion theory of B-lymphocyte tolerance , 1975, The Journal of experimental medicine.
[95] D. Hilbert,et al. Cutting Edge: BLyS Enables Survival of Transitional and Mature B Cells Through Distinct Mediators1 , 2002, The Journal of Immunology.
[96] S. Smith‐Gill,et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice , 1988, Nature.
[97] Kenneth G. C. Smith,et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. , 2006, Arthritis and rheumatism.
[98] M. Genovese,et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. , 2008, Arthritis and rheumatism.
[99] D. Isenberg,et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. , 2005, Rheumatology.
[100] D. Isenberg,et al. B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response , 2007 .
[101] D. Greaves,et al. ΔBAFF, a Splice Isoform of BAFF, Opposes Full-Length BAFF Activity In Vivo in Transgenic Mouse Models1 , 2005, The Journal of Immunology.
[102] M. Tourigny,et al. Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response , 2000, The Journal of experimental medicine.
[103] M. McClain,et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. , 2004, Arthritis and rheumatism.
[104] Beatrice Gralton,et al. Washington DC - USA , 2008 .
[105] K. Kalunian,et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. , 2007, Arthritis and rheumatism.